Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement
Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement
复制标题
DOI：
10.1016/j.biopha.2007.05.004
复制
发表时间：
2007-07-01
影响因子：
7.5
通讯作者：
Suttmann, Henrik
中科院分区：
文献类型：
--
作者：
Brandau, Sven;Suttmann, Henrik
在过去的三十年中，生物反应调节剂牛分枝杆菌卡介苗（BCG）的膀胱内免疫治疗已被确定为预防非肌层浸润性膀胱癌经尿道切除术后局部复发和肿瘤进展的最有效辅助治疗。大量的临床试验已经确立了BCG免疫治疗在泌尿肿瘤学中的重要作用。与此同时，免疫机制的主要原理也被揭示出来。尽管取得了这一成功，但关于其临床应用、作用机制和潜在改进的问题仍然存在。本文综述了BCG免疫治疗的历史时期、目前临床应用的适应症、复杂的作用机制和未来可能的发展。(C)2007年，Elsevier Masson SAS。All rights reserved.
Over the last three decades, intravesical immunotherapy with the biological response modifier Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been established as the most effective adjuvant treatment for preventing local recurrences and tumor progression following transurethral resection of non-muscle invasive bladder cancer. A large number of clinical trials have established a major role for BCG immunotherapy in urological oncology. In parallel, the major principles of the immunological mechanism have been revealed. In spite of this success, questions still remain regarding its clinical use, mechanism of action and potential improvement. This review provides a comprehensive insight into the historical era of BCG immunotherapy, the current indications for clinical application, the complex mechanism of action and possible future developments. (C) 2007 Elsevier Masson SAS. All rights reserved.